SSKN vs. GCTK, PETV, MBOT, NXGL, MHUA, BTCY, PAVM, TTOO, NURO, and VAPO
Should you be buying STRATA Skin Sciences stock or one of its competitors? The main competitors of STRATA Skin Sciences include GlucoTrack (GCTK), PetVivo (PETV), Microbot Medical (MBOT), NEXGEL (NXGL), Meihua International Medical Technologies (MHUA), Biotricity (BTCY), PAVmed (PAVM), T2 Biosystems (TTOO), NeuroMetrix (NURO), and Vapotherm (VAPO). These companies are all part of the "surgical & medical instruments" industry.
STRATA Skin Sciences (NASDAQ:SSKN) and GlucoTrack (NASDAQ:GCTK) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, analyst recommendations, institutional ownership, valuation, media sentiment, risk, profitability and community ranking.
GlucoTrack has lower revenue, but higher earnings than STRATA Skin Sciences. GlucoTrack is trading at a lower price-to-earnings ratio than STRATA Skin Sciences, indicating that it is currently the more affordable of the two stocks.
STRATA Skin Sciences has a beta of 1.53, indicating that its stock price is 53% more volatile than the S&P 500. Comparatively, GlucoTrack has a beta of 0.1, indicating that its stock price is 90% less volatile than the S&P 500.
GlucoTrack has a net margin of 0.00% compared to STRATA Skin Sciences' net margin of -32.47%. STRATA Skin Sciences' return on equity of -52.50% beat GlucoTrack's return on equity.
In the previous week, STRATA Skin Sciences and STRATA Skin Sciences both had 2 articles in the media. GlucoTrack's average media sentiment score of 0.55 beat STRATA Skin Sciences' score of 0.00 indicating that GlucoTrack is being referred to more favorably in the news media.
STRATA Skin Sciences currently has a consensus price target of $3.80, indicating a potential upside of 804.76%. Given STRATA Skin Sciences' higher probable upside, equities analysts clearly believe STRATA Skin Sciences is more favorable than GlucoTrack.
STRATA Skin Sciences received 223 more outperform votes than GlucoTrack when rated by MarketBeat users.
32.4% of STRATA Skin Sciences shares are owned by institutional investors. Comparatively, 10.9% of GlucoTrack shares are owned by institutional investors. 40.4% of STRATA Skin Sciences shares are owned by company insiders. Comparatively, 17.7% of GlucoTrack shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Summary
STRATA Skin Sciences beats GlucoTrack on 10 of the 13 factors compared between the two stocks.
Get STRATA Skin Sciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for SSKN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SSKN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
STRATA Skin Sciences Competitors List
Related Companies and Tools
